research Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis 37 citations , January 2006 in “Carcinogenesis” Antizyme slows skin tumor growth by reducing cell growth in mice.
research IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes 32 citations , December 2019 in “The Journal of clinical investigation/The journal of clinical investigation” A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
research The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis 9 citations , December 2018 in “Cutaneous and Ocular Toxicology” Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.
research Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib 3 citations , November 2024 in “Pediatric Dermatology” Selumetinib causes fewer and less severe skin issues in children than binimetinib.
research Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging 2 citations , May 2008 in “Journal of Clinical Oncology” AZD6244 treatment causes skin aging effects by depleting skin stem cells.